Rising incidence of immunodeficiency diseases and increase in geriatric population are key factors driving market revenue growth
NEW YORK, NY, UNITED STATES, April 15, 2022 /EINPresswire.com/ — Global Intravenous Immunoglobulin (IVIG) market size is expected to reach USD 20.22 Billion in 2030 and register revenue CAGR of 6.9% over the forecast period, according to latest report by Reports and Data. Rising incidence of immunodeficiency diseases and steady increase in geriatric population are key factors expected to drive market revenue growth over the forecast period.
With rise in cases of primary and acquired immunodeficiency diseases and disorders such as hypogammaglobulinemia, immunodeficiency diseases, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre syndrome, Kawasaki disease, healthcare ecosystem gets affected by rising demand to allocate resources in a more diversified manner to fulfil needs of changing healthcare dynamics. Healthcare infrastructure faces more burden with steadily growing pool of patients with immunoglobulin deficiency. With increase in awareness and adoption of IVIG therapies, demand for getting proper treatment rises which creates a strong demand for plasma market. Hence with changing healthcare dynamics, need for proper allocation of resources is of high importance for healthcare management. Proper allocation of resources boosts the entire supply chain and accounts for growth of IVIG market.
Get a sample of the report @
Immunoglobulin helps to treat these immunodeficiency diseases and disorders efficiently and effectively. This drags medical experts for novel immunoglobulin therapies, safe to administer with minimal side effects. In cases of primary immunodeficiency that affects antibody production, immunoglobulin replacement therapies are considered one of the most successful. According to the American College of Rheumatology, intravenous immunoglobulin provides significant-good results and is used for treatments such as Kawasaki disease, a rheumatologic disease in children. IVIG is also used for treating patients with inflammatory muscle diseases, including dermatomyositis, polymyositis, and juvenile dermatomyositis. IVIG is considered first line of treatment for adult Immune Thrombocytopenia (ITP) and is more effective than other conventional therapies. In systematic lupus erythematosus, IVIG is also used as a therapy to boost abnormally low platelet count, or red blood cells count. Thus, with increase in immunodeficiency diseases, neurological and bleeding disorders, high efficacy of IVIG has a significant positive impact on market growth.
However, high cost of IVIG therapies is the primary factor that is expected to hamper market revenue growth. In addition, stringent regulatory policies by various governments will restrain market revenue growth.
Some Key Highlights in the Report
Hypogammaglobulinemia segment is expected to lead in terms of revenue contribution to global market. Hypogammaglobulinemia is the most prevalent primary immunodeficiency and encompasses a majority of immune-compromised patients caused by low antibody levels. Standard treatment for hypogammaglobulinemia is IgG replacement to minimize potentially fatal infection and reduce complications, thus improving patients’ survival and quality of life.
Liquid segment is expected to account for larger market share over the forecast period. Liquid form is more convenient to patients owing to relatively shorter time of infusion process. In addition, ease of preparation and administration for health workers and patients makes it most acceptable which augment growth for this segment.
North America will account for the largest market share in IVIG market over the forecast period due to increasing number of patients with immunology disorders and rising geriatric population
Companies in global market report include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd, Shanghai RAAS Blood Products Co., Ltd, CSL Behring LLC, ADMA Biologics, Inc., Baxalta Inc., Biotest AG, Kedrion Biopharma, Inc., China Biologic Products Holdings, Inc., Octapharma AG, Grifols S.A., Pfizer Inc., and LFB Biomedicaments SA.
In August 2021, ADMA Biologics, Inc. received Food and Drug Administration (FDA) approval for Maryville’s ADMA Biocenters plasma collection facility. Introduction of new plasma collection facility helps to secure raw material plasma supply and helps the company to ensure itself from border market plasma collection and pricing fluctuations.
To know more about the report @
Intravenous Immunoglobin (IVIG) Market Segmentation:
Product Type Outlook (Revenue, USD Billion; (2019-2030)
Immunoglobulin G (IgG)
Immunoglobulin A (IgA)
Immunoglobulin M (IgM)
Immunoglobulin E (IgE)
Immunoglobulin D (IgD)
Application Outlook (Revenue, USD Billion; 2019-2030)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multifocal Motor Neuropathy
Form Outlook (Revenue, USD Billion; 2019-2030)
End-Use Outlook (Revenue, USD Billion; 2019-2030)
Global Intravenous Immunoglobin (IVIG) Market Report: Regional Segmentation
Rest of Europe
Rest of APAC
Rest of LATAM
Middle East & Africa
Rest of MEA
Download Summary @
Global Intravenous Immunoglobin (IVIG) Market: Table of Contents
Chapter 1. Methodology & Sources
1.1. Market Definition
1.2. Research Scope
1.4. Research Sources
1.4.1. Primary Sources
1.4.2. Secondary Sources
1.4.3. Paid Sources
1.5. Market Estimation Technique
Chapter 2. Executive Summary
Chapter 3. Key Insights
Chapter 4. Global Pharma & Healthcare Market Segmentation
4.1. Global Pharma & Healthcare Market COVID-19 Impact Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers’ analysis
4.2.3. Market restraints analysis
4.3. Technological Insights
4.4. Porter’s Five Forces Analysis
4.5. Regulatory Framework
4.6. Price trend Analysis
4.7. Competitive Metric Space Analysis
Request a customization of the report @
Frequently Asked Questions Answered in the Report:
What is the estimated revenue growth rate of the global Intravenous Immunoglobin (IVIG) market over the forecast period?
What are the major factors driving the global market revenue growth?
Which are the leading manufacturers and suppliers in the global Intravenous Immunoglobin (IVIG) market?
Which regional market is expected to lead in terms of revenue share in the global Intravenous Immunoglobin (IVIG) market over the forecast years?
What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis of the market?
Browse More Reports:
Anxiety Disorder and Depression Treatment Market @
AR/VR in Healthcare Market @
Assisted Reproductive Technology (ART) Market @
Bioactive Wound Care Market @
Cardiovascular Devices Market @
DNA and Gene Chip Market @
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Reports and Data
email us here
Visit us on social media:
This news story originally appeared at Health - Trend Magazine on 19 April 2022